# Growth Hormone Axis FAQ > Growth Hormone Axis Research Peptides FAQ — AV Peptide — Evidence-based answers on Growth Hormone Axis research peptides, including MOTS-c, CJC-1295, tesamorelin, ipamorelin, GH, IGF-1, safety, and surrogate endpoints. **QUESTIONS / MEASURED ANSWERS** Direct answers, each bounded by study design, population, and endpoint. ## What does the MOTS-c peptide do? MOTS-c is studied as a mitochondrial-derived signal involved in cellular energy stress and metabolism. Experiments link it to CK2, AMPK-related energy sensing, purine metabolism, and stress-responsive nuclear gene regulation [1][3][5][6]. Animal work reports effects on muscle glucose uptake, physical performance, insulin resistance, and cardiac mitochondrial respiration [1][4][6][7]. Those are preclinical findings. The supplied corpus contains no human efficacy trial showing that external MOTS-c produces these outcomes in people. ## What are the negative side effects of MOTS-c? A reliable human adverse-effect profile has not been established because the source set contains no human intervention trial of external MOTS-c. Human pharmacokinetics and long-term safety also remain unvalidated. That absence is an evidence gap, not evidence of safety. Online symptom reports are anecdotal, not clinical evidence, and research-market identity, purity, and sterility cannot be inferred from animal or cell studies. ## Is MOTS-c an established Growth Hormone Axis peptide? Not by its primary documented mechanism. MOTS-c is encoded within mitochondrial genetic material and is studied through mitochondrial stress, CK2, AMPK-linked metabolism, and nuclear signaling [1][3][5][6]. It does not share the direct GHRH-receptor mechanism of CJC-1295 and tesamorelin or the ghrelin-receptor mechanism of ipamorelin. Its role in this digest is comparative: metabolic relevance does not automatically mean direct GH-axis activity. ## What is CJC-1295? CJC-1295 is a synthetic GHRH analog. It stimulates the pituitary pathway that releases endogenous growth hormone and increases downstream IGF-1 [8][11]. The DAC form binds albumin and is long acting; the no-DAC form lacks that feature and is short acting. Human studies in this corpus focus on pharmacology and biomarkers rather than body-composition or long-term clinical outcomes [10][11][12]. ## What does CJC-1295 do? In small human studies, CJC-1295 increased mean GH and IGF-1 for days, and GH pulsatility remained present during continuous stimulation [11][12]. A small proteomic study also found serum protein changes correlated with IGF-1 [10]. These results demonstrate pathway activation. They do not establish fat loss, muscle gain, sleep improvement, recovery, or longevity because those outcomes were not demonstrated in the cited trials. ## Is CJC-1295 safe? The evidence is insufficient for a general safety conclusion. Human studies in this corpus are small and early, with an emphasis on GH and IGF-1 responses rather than long-term safety [10][11][12]. Sustained axis activation makes fluid balance, glucose regulation, and prolonged IGF-1 exposure relevant concerns, while DAC and no-DAC forms create different exposure patterns. The supplied compliance record lists no approved human indication. ## What is tesamorelin? Tesamorelin is a synthetic GHRH analog that stimulates endogenous GH and downstream IGF-1. It has a specific United States approval to reduce excess abdominal fat in adults with HIV-associated lipodystrophy [14]. Randomized trials in that population measured reductions in visceral and hepatic fat [13][15][17]. That indication should not be generalized into approval for ordinary abdominal weight or broad anti-aging use. ## How does tesamorelin work? Tesamorelin activates GHRH receptors on pituitary somatotroph cells. The resulting signaling increases pulsatile endogenous GH release, which raises hepatic IGF-1 and promotes lipolysis [8][16]. In a short healthy-men study, overnight GH and IGF-1 increased while measured glucose outcomes did not change significantly during the study window [16]. The randomized HIV-lipodystrophy program then connected that mechanism to measured body-composition outcomes [13][15][17]. ## Does tesamorelin reduce belly fat in everyone? The evidence does not support “everyone.” Trials found reduced visceral abdominal fat in adults with HIV-associated lipodystrophy, a specific treatment context and population [13][15][17]. Visceral fat also reaccumulated after discontinuation in the longer program [17]. Those data support the approved narrow indication, not a universal claim for general obesity, cosmetic fat loss, or populations that were not tested. ## What is ipamorelin? Ipamorelin is a synthetic pentapeptide and selective agonist of the GHS-R1a ghrelin receptor. It triggers endogenous GH release through a different receptor from GHRH analogs. Early human modeling found a short terminal half-life and a discrete GH pulse after studied intravenous exposure [21]. Ipamorelin has no approved human indication in the supplied record. ## What are the risks of ipamorelin? Long-term human risk is unresolved. The controlled perioperative trial was brief and cannot establish chronic safety [20]. A different ghrelin-receptor agonist caused cardiac injury in a chronic rat toxicology study, which raises a class-level question but is not direct evidence of ipamorelin harm [19]. GH-related fluid and glucose effects, appetite signaling, unregulated research-material quality, and the absence of a long-term human safety database all limit confidence. ## Why can GH or IGF-1 not stand in for a clinical outcome? GH and IGF-1 show that the signaling axis responded. They do not directly measure visceral fat, strength, recovery, quality of life, or disease events. CJC-1295 produced sustained biomarker changes without a comparable outcome program in this corpus [11][12]. Tesamorelin separately measured visceral and liver fat in randomized studies [13][15]. Ipamorelin generated an acute GH pulse, yet its controlled postoperative trial missed the primary efficacy endpoint [20][21]. Each conclusion must stop at the endpoint measured. --- AV Peptide is an independent GH/IGF-1 evidence digest that keeps hormone signals, tissue outcomes, and medical decisions in separate columns.